Delving into the Latest Updates on Ariston Pharmaceuticals, Inc. with Synapse

概览

关联

1

项与 Ariston Pharmaceuticals, Inc. 相关的药物

AST-117

靶点-

作用机制-

在研机构-

原研机构

TG Therapeutics, Inc.

在研适应症-

非在研适应症

焦虑症

最高研发阶段终止

首次获批国家/地区-

首次获批日期-

1

项与 Ariston Pharmaceuticals, Inc. 相关的临床试验

NCT00285402

/ Unknown status临床2期

Intranasal AST-726 Treatment for Prophylaxis of Migraine: A Placebo-Controlled Clinical Study

The purpose of this migraine prevention study is to evaluate the efficacy and safety of AST-726 in moderate to severe migraine patients at one of two doses compared to placebo and compared to a baseline period as measured by a reduction in the number of migraine days.

开始日期2007-05-01

申办/合作机构

Ariston Pharmaceuticals, Inc.

100 项与 Ariston Pharmaceuticals, Inc. 相关的临床结果

登录后查看更多信息

0 项与 Ariston Pharmaceuticals, Inc. 相关的专利（医药）

登录后查看更多信息

100 项与 Ariston Pharmaceuticals, Inc. 相关的药物交易

登录后查看更多信息

100 项与 Ariston Pharmaceuticals, Inc. 相关的转化医学

登录后查看更多信息